Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

about

Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

Item

http://www.wikidata.org/entity/Q55402302

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Prognostic value of early 18F- ...... primary CNS lymphoma patients.

@en

Prognostic value of early 18F- ...... primary CNS lymphoma patients.

@nl

type

Item

label

Prognostic value of early 18F- ...... primary CNS lymphoma patients.

@en

Prognostic value of early 18F- ...... primary CNS lymphoma patients.

@nl

prefLabel

Prognostic value of early 18F- ...... primary CNS lymphoma patients.

@en

Prognostic value of early 18F- ...... primary CNS lymphoma patients.

@nl

P1476

Prognostic value of early 18F- ...... primary CNS lymphoma patients.

@en

P2093

Aude Quentin

http://www.w3.org/2001/XMLSchema#string

Barbara Burroni

http://www.w3.org/2001/XMLSchema#string

Benedicte Deau

http://www.w3.org/2001/XMLSchema#string

Carole Soussain

http://www.w3.org/2001/XMLSchema#string

Caroline Houillier

http://www.w3.org/2001/XMLSchema#string

Charles Nguyen

http://www.w3.org/2001/XMLSchema#string

Diane Damotte

http://www.w3.org/2001/XMLSchema#string

Didier Bouscary

http://www.w3.org/2001/XMLSchema#string

Edouard Dezamis

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Le Ray

http://www.w3.org/2001/XMLSchema#string

P2860

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.

Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

The utility of body FDG PET in staging primary central nervous system lymphoma

Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

P304

16822-16831

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24706

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jerome Tamburini

Sawsen Salah

P577

2018-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29682187

http://www.w3.org/2001/XMLSchema#string

P932

5908288

http://www.w3.org/2001/XMLSchema#string